The Best (And Worst) Of The Mayne Pharma Group Ltd (MYX) HY Report

Mayne Pharma Group Ltd (ASX:MYX) reported half year earnings this morning for the period ended 31st December 2018.

You’re reading a free article on Rask. Join 4,000+ Australians who get our expert advice, tools, exclusive research and investment recommendations. Get your 30-day trial for $1! Learn more

Mayne Pharma Group Ltd (ASX: MYX) reported half-year earnings this morning for the period ended 31st December 2018.

Mayne Pharma is an Australian specialist pharmaceutical company, creating commercialised and generic products you’ll find in pharmacies across Australia. Mayne Pharma’s history started in South Australia, but today it develops most of its drugs in Australia and the USA.

The 5 Key Points

  • Revenue increased by 13% to $274.4 million
  • Reported EBITDA increased by 184% to $65.4 million (Video: What is EBITDA?)
  • Reported net profit (NPAT) of $2.6 million, which follows a loss in the prior corresponding period
  • Net operating cash flow increased 11% to $53.5 million
  • Received US Food and Drug Administration (FDA) approval for TOLSURA, an antifungal capsule

Analyst Targets

Bloomberg estimates for NPAT were $26.7 million Mayne Pharma failed to reached the targets with their underlying NPAT of $21.1 million and reported NPAT of $2.6 million.

Management Commentary

Mayne Pharma’s Chief Executive Officer, Mr Scott Richards, noted, “Specialty Brands tripled sales and gross profit with FABIOR, SORILUX and DORYX all contributing to growth versus pcp, and Generic Products reported much stronger gross profit despite the entrance of a number of new competitors into the dofetilide market.”

On some of the highlights of the first half, he noted, “The first half saw the completion of many strategic investments such as the acquisition of two dermatology products… We also invested in a new hospital-based field team to promote TOLSURA which was approved by the FDA during the period, and lastly we took control of the SUBA-itraconazole BCCNS program from HedgePath Pharmaceuticals, Inc.”

Outlook

online pharmacy lariam over the counter with best prices today in the USA

Mayne Pharma continues to focus on the US pharmaceutical market as it is by far the largest market, making up 44% of global sales. One strategy the company plans to use is vertical integration, stating that the company, “remains focused on participating in other parts of the value chain and finding more efficient and cost-effective ways of getting products to patients.”

online pharmacy buy lasix no prescription

Mayne Pharma also expects to see increased growth from the launch of their two new brands, LEXETTE and TOLSURA. For more insight into the valuation of Mayne Pharma, check out this Rask Media article.

[ls_content_block id=”14945″ para=”paragraphs”]

Disclaimer: At the time of writing, Max does not own shares in any of the companies mentioned.

A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

How can Rask help you?

About Rask

Learn more about us, our your community and our mission.

Rask investing philosophy

Nearly 15 years later.
It's still a work in progress.

Online investment community

You won't find our investment community on Facebook or Reddit because it's secure, free and available now.

Join 250,000+ podcast listeners

250,000 investors tune into the Rask podcasts every month. Find out why.

Find a financial planner

Australia's financial experts. At your doorstep.

Free finance courses

35,000 students have enrolled in free Rask courses. We're on a mission to 100,000.

Subscribe to Rask's free investor newsletter

53,000 Australian investors subscribe to our Sunday newsletter... and love it! It's free.

$50 million invested

We manage almost $50 million on behalf of Aussies. Discover how you can invest with us.

Better investing starts here.

Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best  insights.

Subscribe to Rask's free investor newsletter

Kick off your week with our pick of podcasts, courses and investing resources to keep your finger on the Rask pulse!

Here you go: A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.